文献(401-500)

401. Eschalier R, McMurray JJ, Swedberg K, et al. EMPHASIS-HF Investigators.Safety and efficacy of eplerenone in patients at high risk for

hyperkalemia and/or worsening renal function: analyses of the EMPHASIS- HF study subgroups (Eplerenone in Mild Patients

Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 2013; 62: 1585-1593. PMID: 23810881

402. Cosín J, Díez J. TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4: 507-

513. PMID: 12167392

403. Shlipak MG, Smith GL, Rathore SS, et al. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin

intervention group trial. J Am Soc Nephrol 2004; 15: 2195-2203. PMID: 15284305

404. Gheorghiade M, Böhm M, Greene SJ, et al. ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality

and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013; 309: 1125-

1135. PMID: 23478743

405. Nigwekar SU, Navaneethan SD, Parikh CR, et al. Atrial natriuretic peptide for management of acute kidney injury: a systematic review

and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 261-272. PMID:19073785

406. Matsue Y, Suzuki M, Torii S, et al. Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction. J

Card Fail 2016; 22: 423-432. PMID: 26915749

407. 日本痛風・核酸代謝学会ガイドライン改訂委員会．高尿酸血症・痛風の治療ガイドライン第2版．メディカルレビュー社 2010.

408. Givertz MM, Anstrom KJ, Redfield MM, et al. NHLBI Heart Failure Clinical Research Network. Effects of Xanthine Oxidase Inhibition in

Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.

Circulation 2015; 131: 1763-1771. PMID: 25986447

409. Global Initiative for Asthma. 2016 GINA Report, Global Strategy for Asthma Management and Prevention. http://ginasthma.org/wp-

content/ uploads/2016/04/wms-GINA-2016-main-report-final.pdf

410. Global Initiative for Chronic Obstructive Lung Disease. GOLD 2017: Global Strategy for the Diagnosis, Management and Prevention of

COPD. http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/

411. Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res 2013; 162: 237-251. PMID:

23727296

412. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary

disease and chronic heart failure. J Am Coll Cardiol 2007; 49: 171-180. PMID: 17222727

413 Yoshihisa A, Takiguchi M, Shimizu T, et al. Cardiovascular function and prognosis of patients with heart failure coexistent with chronic

obstructive pulmonary disease. J Cardiol 2014; 64: 256-264. PMID: 24674751

414. Chen W, Thomas J, Sadatsafavi M, et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a

systematic review and meta-analysis. Lancet Respir Med 2015; 3: 631-639. PMID: 26208998

415. Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary

disease. Eur Heart J 2005; 26: 1887-1894. PMID: 15860516

416. Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health

services. Eur Heart J 2013; 34: 2795-2803. PMID: 23832490

417. Lipworth B, Wedzicha J, Devereux G, et al. Beta-blockers in COPD: time for reappraisal. Eur Respir J 2016; 48: 880-888. PMID:

27390282

418. Morales DR, Jackson C, Lipworth BJ, et al. Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and

meta-analysis of randomized controlled trials. Chest 2014; 145: 779- 786. PMID: 24202435

419. Forth R, Montgomery H. ACE in COPD: a therapeutic target? Thorax 2003; 58: 556-558. PMID: 12832663

420. Kajimoto K, Sato N, Takano T. investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) registry. Association

between anemia, clinical features and outcome in patients hospitalized for acute heart failure syndromes. Eur Heart J Acute Cardiovasc

Care 2015; 4: 568-576. PMID: 25315117

421. Yamauchi T, Sakata Y, Takada T, et al. CHART-2 investigators. Prognostic Impact of Anemia in Patients With Chronic Heart Failure-

With Special Reference to Clinical Background: Report From the CHART-2 Study. Circ J 2015; 79: 1984-1993. PMID: 26050711

422. Oldenburg O, Lamp B, Faber L, et al. Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of

prevalence in and characteristics of 700 patients. Eur J Heart Fail 2007; 9: 251-257. PMID: 17027333

423. Yumino D, Wang H, Floras JS, et al. Prevalence and physiological predictors of sleep apnea in patients with heart failure and systolic

dysfunction. J Card Fail 2009; 15: 279-285. PMID: 19398074

424. Javaheri S. Sleep disorders in systolic heart failure: a prospective study of 100 male patients. The final report. Int J Cardiol 2006; 106:

21-28. PMID: 16321661

425. Chan J, Sanderson J, Chan W, et al. Prevalence of sleep-disordered breathing in diastolic heart failure. Chest 1997; 111: 1488-1493.

PMID: 9187161

426. Bitter T, Faber L, Hering D, et al. Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. Eur J Heart Fail

2009; 11: 602-608. PMID: 19468022

427. 日本循環器学会．循環器病の診断と治療に関するガイドライン．循環器領域における睡眠呼吸障害の診断・治療に関するガイドライン．Circ J

2010; 74 Suppl II: 963-1084.

428. Kasai T, Floras JS, Bradley TD. Sleep apnea and cardiovascular disease: a bidirectional relationship. Circulation 2012; 126: 1495-1510.

PMID: 22988046

429. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or

without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-1053. PMID: 15781100

430. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart

failure: the sleep heart health study. Circulation 2010; 122: 352-360.PMID: 20625114

431. Kasai T. Sleep apnea and heart failure. J Cardiol 2012; 60: 78-85. PMID: 22824295

432. Yumino D, Redolfi S, Ruttanaumpawan P, et al. Nocturnal rostral fluid shift: a unifying concept for the pathogenesis of obstructive and

central sleep apnea in men with heart failure. Circulation 2010; 121:1598-1605. PMID: 20351237

433. Wang H, Parker JD, Newton GE, et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol

2007; 49: 1625-1631. PMID: 17433953

434. Javaheri S, Shukla R, Zeigler H, et al. Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors

of mortality in systolic heart failure. J Am Coll Cardiol 2007; 49:2028-2034. PMID: 17512359

435. Arzt M, Young T, Finn L, et al. Sleepiness and sleep in patients with both systolic heart failure and obstructive sleep apnea. Arch Intern

Med 2006; 166: 1716-1722. PMID: 16983049

436. Kaneko Y, Floras JS, Usui K, et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and

obstructive sleep apnea. N Engl J Med 2003; 348: 1233-1241. PMID:12660387

437. Sun H, Shi J, Li M, et al. Impact of continuous positive airway pressure treatment on left ventricular ejection fraction in patients with

obstructive sleep apnea: a meta-analysis of randomized controlled trials. PLoS One 2013; 8: e62298. PMID: 23650511

438. Kasai T, Narui K, Dohi T, et al. Prognosis of patients with heart failure and obstructive sleep apnea treated with continuous positive

airway pressure. Chest 2008; 133: 690-696. PMID: 18198253

439. Damy T, Margarit L, Noroc A, et al. Prognostic impact of sleep-disordered breathing and its treatment with nocturnal ventilation for

chronic heart failure. Eur J Heart Fail 2012; 14: 1009-1019. PMID: 22730336

440. Bradley TD, Logan AG, Kimoff RJ, et al. CANPAP Investigators. Continuous positive airway pressure for central sleep apnea and heart

failure. N Engl J Med 2005; 353: 2025-2033. PMID: 16282177

441. Arzt M, Floras JS, Logan AG, et al. CANPAP Investigators. Suppression of central sleep apnea by continuous positive airway pressure

and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with

Central Sleep Apnea and Heart Failure Trial (CANPAP). Circulation 2007; 115: 3173-3180. PMID: 17562959

442. Kasai T, Kasagi S, Maeno K, et al. Adaptive servo-ventilation in cardiac function and neurohormonal status in patients with heart failure

and central sleep apnea nonresponsive to continuous positive airway pressure. JACC Heart Fail 2013; 1: 58-63. PMID: 24621799

443. Kasai T, Usui Y, Yoshioka T, et al. JASV Investigators. Effect of flow-triggered adaptive servo-ventilation compared with continuous

positive airway pressure in patients with chronic heart failure with coexisting obstructive sleep apnea and Cheyne-Stokes respiration.

Circ Heart Fail 2010; 3: 140-148. PMID: 19933407

444. Sharma BK, Bakker JP, McSharry DG, et al. Adaptive servoventilation for treatment of sleep-disordered breathing in heart failure: a

systematic review and meta-analysis. Chest 2012; 142: 1211-1221. PMID: 22722232

445. Aurora RN, Chowdhuri S, Ramar K, et al. The treatment of central sleep apnea syndromes in adults: practice parameters with an

evidence- based literature review and meta-analyses. Sleep 2012; 35: 17- 40. PMID: 22215916

446. Yoshihisa A, Shimizu T, Owada T, et al. Adaptive servo ventilation improves cardiac dysfunction and prognosis in chronic heart failure

patients with Cheyne-Stokes respiration. Int Heart J 2011; 52: 218-223. PMID: 21828947

447. Javaheri S. Pembrey’s dream: the time has come for a long-term trial of nocturnal supplemental nasal oxygen to treat central sleep

apnea in congestive heart failure. Chest 2003; 123: 322-325. PMID: 12576341

448. Shigemitsu M, Nishio K, Kusuyama T, et al. Nocturnal oxygen thera py prevents progress of congestive heart failure with central sleep

apnea. Int J Cardiol 2007; 115: 354-360. PMID: 16806535

449. Toyama T, Seki R, Kasama S, et al. Effectiveness of nocturnal home oxygen therapy to improve exercise capacity, cardiac function and

cardiac sympathetic nerve activity in patients with chronic heart failure and central sleep apnea. Circ J 2009; 73: 299-304. PMID:

19122308

450. Sasayama S, Izumi T, Seino Y, et al. CHF-HOT Study Group. Effects of nocturnal oxygen therapy on outcome measures in patients with

chronic heart failure and cheyne-stokes respiration. Circ J 2006; 70: 1-7. PMID: 16377916

451. Sasayama S, Izumi T, Matsuzaki M, et al. CHF-HOT Study Group. Improvement of quality of life with nocturnal oxygen therapy in heart

failure patients with central sleep apnea. Circ J 2009; 73: 1255-1262. PMID: 19448327

452. Mebazaa A, Gheorghiade M, Piña IL, et al. Practical recommendations for prehospital and early in-hospital management of patients

presenting with acute heart failure syndromes. Crit Care Med 2008; 36: S129-S139. PMID: 18158472

453. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol

1967; 20: 457-464. PMID: 6059183

454. Mebazaa A, Tolppanen H, Mueller C, et al. Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. Intensive

Care Med 2016; 42: 147-163. PMID: 26370690

455. 日本循環器学会．急性および慢性心筋炎の診断・治療に関するガイドライン（2009年改訂版）．

http://www.j-circ.or.jp/guideline/pdf/JCS2009_izumi_h.pdf

456. 日本循環器学会．ST上昇型急性心筋梗塞の診療に関するガイドライン（2013年改訂版）．

http://www.j-circ.or.jp/guideline/pdf/JCS2013_kimura_h.pdf

457. 日本循環器学会．非ST上昇型急性冠症候群の診療に関するガイドライン（2012年改訂版）．

http://www.j-circ.or.jp/guideline/pdf/JCS2012_kimura_h.pdf

458. 日本循環器学会．肺血栓塞栓症および深部静脈血栓症の診断、治療、予防に関するガイドライン（2009年改訂版）．

http://www.j-circ.or.jp/guideline/pdf/JCS2009_andoh_h.pdf

459. Stevenson LW. Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail 1999; 1: 251-257. PMID: 10935671

460. Kajimoto K, Sato N, Sakata Y, et al. Acute Decompensated Heart Failure Syndromes (ATTEND) investigators. Relationship between

systolic blood pressure and preserved or reduced ejection fraction at admission in patients hospitalized for acute heart failure syndromes.

Int J Cardiol 2013; 168: 4790-4795. PMID: 23962780

461. Bristow MR, Shakar SF, Linseman JV, et al. Inotropes and beta- blockers: is there a need for new guidelines? J Card Fail 2001; 7:

8-12. PMID: 11605160

462. Vismara LA, Leaman DM, Zelis R. The effects of morphine on venous tone in patients with acute pulmonary edema. Circulation 1976;

54: 335-337. PMID: 939031

463. Iakobishvili Z, Cohen E, Garty M, et al. Heart Failure Survey in Isarel (HFSIS) Investigators. Use of intravenous morphine for acute

decompensated heart failure in patients with and without acute coronary syndromes. Acute Card Care 2011; 13: 76-80. PMID: 21627393

464. Peacock WF, Hollander JE, Diercks DB, et al. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis.

Emerg Med J 2008; 25: 205-209. PMID: 18356349

465. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose

furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998; 351: 389-393. PMID: 9482291

466. Matsue Y, Damman K, Voors AA, et al. Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure.

J Am Coll Cardiol 2017; 69: 3042-3051. PMID: 28641794

467. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001; 96: 132-143. PMID: 11805380

468. Dormans TP, van Meyel JJ, Gerlag PG, et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus

continuous infusion. J Am Coll Cardiol 1996; 28: 376-382. PMID: 8800113

469. Tsutamoto T, Kinoshita M, Nakae I, et al. Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart

failure. Am Heart J 1994; 127: 866-873. PMID: 8154425

470. Tsutamoto T, Kinoshita M, Hisanaga T, et al. Comparison of hemodynamic effects and plasma cyclic guanosine monophosphate of

nicorandil and nitroglycerin in patients with congestive heart failure. Am J Cardiol 1995; 75: 1162-1165. PMID: 7762505

471. Tanaka K, Kato K, Takano T, et al. Acute effects of intravenous nicorandil on hemodynamics in patients hospitalized with acute

decompensated heart failure. J Cardiol 2010; 56: 291-299. PMID:20709498

472. Suwa M, Seino Y, Nomachi Y, et al. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in

the ‘real world’ of therapy. Circ J 2005; 69: 283-290. PMID:15731532

473. ドブタミン研究会．ポンプ不全に対するドブタミン，ドパミンの薬剤効果の比較―多施設共同研究の集計．最新医学 1984; 39:1657-1672.

474. Spear GS. Eosinophilic explant carditis with eosinophilia: ?Hypersensitivity to dobutamine infusion. J Heart Lung Transplant 1995;

14: 755-760. PMID: 7578186

475. O’Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in

patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999; 138: 78-

86. PMID: 10385768

476. Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of

the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail 2010; 16: 922-930. PMID: 21111980

477. Bellomo R, Chapman M, Finfer S, et al. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Low-dose

dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Lancet 2000; 356: 2139-2143. PMID:

11191541

478. Chen HH, Anstrom KJ, Givertz MM, et al. NHLBI Heart Failure Clinical Research Network. Low-dose dopamine or low-dose nesiritide

in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 2013; 310: 2533-2543. PMID:

24247300

479. Triposkiadis FK, Butler J, Karayannis G, et al. Efficacy and safety of high dose versus low dose furosemide with or without dopamine

infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. Int J Cardiol 2014; 172: 115-121. PMID:

24485633

480. Ribner HS, Plucinski DA, Hsieh AM, et al. Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due

to dilated cardiomyopathy: a hemodynamic-hormonal study. Am J Cardiol 1985; 56: 896-904. PMID: 3904388

481. Seino Y, Momomura S, Takano T, et al. Japan Intravenous Milrinone Investigators. Multicenter, double-blind study of intravenous

milrinone for patients with acute heart failure in Japan. Crit Care Med 1996; 24: 1490-1497. PMID: 8797620

482. Lowes BD, Tsvetkova T, Eichhorn EJ, et al. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J

Cardiol 2001; 81: 141-149. PMID: 11744130

483. Guyton AC, Lindsey AW. Effect of elevated left atrial pressure and decreased plasma protein concentration on the development of

pulmonary edema. Circ Res 1959; 7: 649-657. PMID: 13663218

484. Johnson A, Mackway-Jones K. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary.

Frusemide or nitrates in acute left ventricular failure. Emerg Med J 2001;18: 59-60. PMID: 11310465

485. Brochard L. Mechanical ventilation: invasive versus noninvasive. Eur Respir J Suppl 2003; 47: 31s-37s. PMID: 14621115

486. MacIntyre NR, Cook DJ, Ely EW, et al. Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task

force facilitated by the American College of Chest Physicians; the American Association for Respiratory Care; and the American College

of Critical Care Medicine. Chest 2001; 120: 375S-395S. PMID: 11742959

487. Hernández G, Vaquero C, González P, et al. Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on

Reintubation in Low-Risk Patients: A Randomized Clinical Trial. JAMA 2016; 315: 1354-1361. PMID: 26975498

488. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease:

a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to

Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of

Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic

Surgeons. J Am Coll Cardiol 2006; 48: e1-148. PMID: 16875962

489. Pappas PJ, Cernaianu AC, Baldino WA, et al. Ventricular free-wall rupture after myocardial infarction. Treatment and outcome. Chest

1991; 99: 892-895. PMID: 2009791

490. Thompson CR, Buller CE, Sleeper LA, et al. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial

infarction: a report from the SHOCK Trial Registry. SHould we use emergently revascularize Occluded Coronaries in cardiogenic shocK?

J Am Coll Cardiol 2000; 36: 1104-1109. PMID: 10985712

491. 玉城雄也，小西治美，堀池聖子，他．重症心不全患者に対する心臓集中治療室での早期心臓リハビリテーションプログラムの導

入．心臓リハビリテーション 2016; 22: 71-76.

492. Dor V, Sabatier M, Di Donato M, et al. Efficacy of endoventricular patch plasty in large postinfarction akinetic scar and severe left

ventricular dysfunction: comparison with a series of large dyskinetic scars. J Thorac Cardiovasc Surg 1998; 116: 50-59. PMID: 9671897

493. Jones RH, Velazquez EJ, Michler RE, et al. STICH Hypothesis 2 Investigators. Coronary bypass surgery with or without surgical

ventricular reconstruction. N Engl J Med 2009; 360: 1705-1717. PMID: 19329820

494. Kainuma S, Taniguchi K, Toda K, et al. Restrictive mitral annuloplasty with or without surgical ventricular reconstruction in ischaemic

cardiomyopathy: impacts on neurohormonal activation, reverse left ventricular remodelling and survival. Eur J Heart Fail 2014; 16: 189-

200. PMID: 24464828

495. Wakasa S, Matsui Y, Isomura T, et al. Risk scores for predicting mortality after surgical ventricular reconstruction for ischemic

cardiomyopathy: results of a Japanese multicenter study. J Thorac Cardiovasc Surg 2014; 147: 1868-1874, 1874.e1-e2. PMID: 23968870

496. 日本循環器学会．循環器病ガイドシリーズ2014年度版．先天性心疾患、心臓大血管の構造的疾患（structural heart disease）に対す

るカテーテル治療のガイドライン．http://www.j-circ.or.jp/guideline/pdf/JCS2014_nakanishi_h.pdf

497. Leon MB, Smith CR, Mack M, et al. PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients

who cannot undergo surgery. N Engl J Med 2010; 363: 1597-1607. PMID: 20961243

498. Kapadia SR, Leon MB, Makkar RR, et al. PARTNER trial investigators. 5-year outcomes of transcatheter aortic valve replacement

compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 2015;

385: 2485-2491. PMID: 25788231

499. Reardon MJ, Adams DH, Kleiman NS, et al. 2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic

Valve Replacement. J Am Coll Cardiol 2015; 66: 113-121. PMID: 26055947

500. Adams DH, Popma JJ, Reardon MJ, et al. U.S. CoreValve Clinical Investigators. Transcatheter aortic-valve replacement with a self-

expanding prosthesis. N Engl J Med 2014; 370: 1790-1798. PMID: 24678937